Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients.

AIDS (London, England) - 23 Apr 2007

Malet Isabelle, Wirden Marc, Derache Anne, Simon Anne, Katlama Christine, Calvez Vincent, Marcelin Anne-Geneviève

Abstract excerpt

Sequences from 82 protease inhibitors (PI)-experienced patients were analysed for the presence of previously described in-vitro resistance mutations to PA-457 located in the C-terminal capside (H226Y, L231F, L231M) and in the N-terminal SP1 (A1V, A3T, A3V) within the CA-SP1 boundary domain. Overall, the CA-SP1 cleavage site was highly conserved in PI pre-treated patients and only one patient showed an L231M...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to gag Gene Products, Human Immunodeficiency Virus

Share to Gene Products, gag

Share to HIV Protease Inhibitors

Share to Succinates

Share to Triterpenes

Source

Identifiers

PMID: 17415044
DOI: 10.1097/QAD.0b013e3280b079d9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients.PMID 17415044Read ↗

The maturation inhibitor bevirimat (PA-457) can be active in patients carrying HIV type-1 non-B subtypes and recombinants.Semantic proximity Read ↗

High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor.Semantic proximity Read ↗

Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat.Semantic proximity Read ↗

In Vitro Resistance to the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PA-457 (Bevirimat)Semantic proximity Read ↗

Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors.Semantic proximity Read ↗

Determinants of activity of the HIV-1 maturation inhibitor PA-457Semantic proximity Read ↗

Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.Semantic proximity Read ↗

Human Immunodeficiency Virus Gag and protease: partners in resistance.Semantic proximity Read ↗

Insights into the activity of maturation inhibitor PF-46396 on HIV-1 clade C.Semantic proximity Read ↗

HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat.Semantic proximity Read ↗

Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance.Semantic proximity Read ↗

A Single Polymorphism in HIV-1 Subtype C SP1 Is Sufficient To Confer Natural Resistance to the Maturation Inhibitor BevirimatSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.